These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

374 related articles for article (PubMed ID: 28376184)

  • 21. A Circulating Panel of circRNA Biomarkers for the Noninvasive and Early Detection of Pancreatic Ductal Adenocarcinoma.
    Xu C; Jun E; Okugawa Y; Toiyama Y; Borazanci E; Bolton J; Taketomi A; Kim SC; Shang D; Von Hoff D; Zhang G; Goel A
    Gastroenterology; 2024 Jan; 166(1):178-190.e16. PubMed ID: 37839499
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Identification of Serum Biomarker Panels for the Early Detection of Pancreatic Cancer.
    Song J; Sokoll LJ; Pasay JJ; Rubin AL; Li H; Bach DM; Chan DW; Zhang Z
    Cancer Epidemiol Biomarkers Prev; 2019 Jan; 28(1):174-182. PubMed ID: 30333219
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Serum Biomarker Signature-Based Liquid Biopsy for Diagnosis of Early-Stage Pancreatic Cancer.
    Mellby LD; Nyberg AP; Johansen JS; Wingren C; Nordestgaard BG; Bojesen SE; Mitchell BL; Sheppard BC; Sears RC; Borrebaeck CAK
    J Clin Oncol; 2018 Oct; 36(28):2887-2894. PubMed ID: 30106639
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Periostin and CA242 as potential diagnostic serum biomarkers complementing CA19.9 in detecting pancreatic cancer.
    Dong D; Jia L; Zhang L; Ma N; Zhang A; Zhou Y; Ren L
    Cancer Sci; 2018 Sep; 109(9):2841-2851. PubMed ID: 29945294
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Development of serum parameters panels for the early detection of pancreatic cancer.
    Zhang P; Zou M; Wen X; Gu F; Li J; Liu G; Dong J; Deng X; Gao J; Li X; Jia X; Dong Z; Chen L; Wang Y; Tian Y
    Int J Cancer; 2014 Jun; 134(11):2646-55. PubMed ID: 24615168
    [TBL] [Abstract][Full Text] [Related]  

  • 26. An Exosome-based Transcriptomic Signature for Noninvasive, Early Detection of Patients With Pancreatic Ductal Adenocarcinoma: A Multicenter Cohort Study.
    Nakamura K; Zhu Z; Roy S; Jun E; Han H; Munoz RM; Nishiwada S; Sharma G; Cridebring D; Zenhausern F; Kim S; Roe DJ; Darabi S; Han IW; Evans DB; Yamada S; Demeure MJ; Becerra C; Celinski SA; Borazanci E; Tsai S; Kodera Y; Park JO; Bolton JS; Wang X; Kim SC; Von Hoff D; Goel A
    Gastroenterology; 2022 Nov; 163(5):1252-1266.e2. PubMed ID: 35850192
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Validation of four candidate pancreatic cancer serological biomarkers that improve the performance of CA19.9.
    Makawita S; Dimitromanolakis A; Soosaipillai A; Soleas I; Chan A; Gallinger S; Haun RS; Blasutig IM; Diamandis EP
    BMC Cancer; 2013 Sep; 13():404. PubMed ID: 24007603
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Detection of early pancreatic ductal adenocarcinoma with thrombospondin-2 and CA19-9 blood markers.
    Kim J; Bamlet WR; Oberg AL; Chaffee KG; Donahue G; Cao XJ; Chari S; Garcia BA; Petersen GM; Zaret KS
    Sci Transl Med; 2017 Jul; 9(398):. PubMed ID: 28701476
    [TBL] [Abstract][Full Text] [Related]  

  • 29. High Detection Rates of Pancreatic Cancer Across Stages by Plasma Assay of Novel Methylated DNA Markers and CA19-9.
    Majumder S; Taylor WR; Foote PH; Berger CK; Wu CW; Mahoney DW; Bamlet WR; Burger KN; Postier N; de la Fuente J; Doering KA; Lidgard GP; Allawi HT; Petersen GM; Chari ST; Ahlquist DA; Kisiel JB
    Clin Cancer Res; 2021 May; 27(9):2523-2532. PubMed ID: 33593879
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Identification of a novel serum biomarker for pancreatic cancer, C4b-binding protein α-chain (C4BPA) by quantitative proteomic analysis using tandem mass tags.
    Sogawa K; Takano S; Iida F; Satoh M; Tsuchida S; Kawashima Y; Yoshitomi H; Sanda A; Kodera Y; Takizawa H; Mikata R; Ohtsuka M; Shimizu H; Miyazaki M; Yokosuka O; Nomura F
    Br J Cancer; 2016 Oct; 115(8):949-956. PubMed ID: 27657339
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Elevated serum CA19-9 level is a promising predictor for poor prognosis in patients with resectable pancreatic ductal adenocarcinoma: a pilot study.
    Dong Q; Yang XH; Zhang Y; Jing W; Zheng LQ; Liu YP; Qu XJ
    World J Surg Oncol; 2014 Jun; 12():171. PubMed ID: 24890327
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A rigorous multi-laboratory study of known PDAC biomarkers identifies increased sensitivity and specificity over CA19-9 alone.
    Haab B; Qian L; Staal B; Jain M; Fahrmann J; Worthington C; Prosser D; Velokokhatnaya L; Lopez C; Tang R; Hurd MW; Natarajan G; Kumar S; Smith L; Hanash S; Batra SK; Maitra A; Lokshin A; Huang Y; Brand RE
    Cancer Lett; 2024 Nov; 604():217245. PubMed ID: 39276915
    [TBL] [Abstract][Full Text] [Related]  

  • 33. THBS2/CA19-9 Detecting Pancreatic Ductal Adenocarcinoma at Diagnosis Underperforms in Prediagnostic Detection: Implications for Biomarker Advancement.
    Udgata S; Takenaka N; Bamlet WR; Oberg AL; Yee SS; Carpenter EL; Herman D; Kim J; Petersen GM; Zaret KS
    Cancer Prev Res (Phila); 2021 Feb; 14(2):223-232. PubMed ID: 33067248
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A Plasma-Derived Protein-Metabolite Multiplexed Panel for Early-Stage Pancreatic Cancer.
    Fahrmann JF; Bantis LE; Capello M; Scelo G; Dennison JB; Patel N; Murage E; Vykoukal J; Kundnani DL; Foretova L; Fabianova E; Holcatova I; Janout V; Feng Z; Yip-Schneider M; Zhang J; Brand R; Taguchi A; Maitra A; Brennan P; Max Schmidt C; Hanash S
    J Natl Cancer Inst; 2019 Apr; 111(4):372-379. PubMed ID: 30137376
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Serum high mobility group box-1 is a powerful diagnostic and prognostic biomarker for pancreatic ductal adenocarcinoma.
    Chung HW; Lim JB; Jang S; Lee KJ; Park KH; Song SY
    Cancer Sci; 2012 Sep; 103(9):1714-21. PubMed ID: 22703527
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Early detection of pancreatic cancer by liquid biopsy "PANLIPSY": a french nation-wide study project.
    Bardol T; Dujon AM; Taly V; Dunyach-Remy C; Lavigne JP; Costa-Silva B; Kurma K; Eslami-S Z; Cayrefourcq L; Canivet C; Muscari F; Bournet B; Alix-Panabières C
    BMC Cancer; 2024 Jun; 24(1):709. PubMed ID: 38853244
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Serum dickkopf-1 is a novel serological biomarker for the diagnosis and prognosis of pancreatic cancer.
    Han SX; Zhou X; Sui X; He CC; Cai MJ; Ma JL; Zhang YY; Zhou CY; Ma CX; Varela-Ramirez A; Zhu Q
    Oncotarget; 2015 Aug; 6(23):19907-17. PubMed ID: 26101916
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Serum tumor antigen REG4 as a diagnostic biomarker in pancreatic ductal adenocarcinoma.
    Takayama R; Nakagawa H; Sawaki A; Mizuno N; Kawai H; Tajika M; Yatabe Y; Matsuo K; Uehara R; Ono K; Nakamura Y; Yamao K
    J Gastroenterol; 2010; 45(1):52-9. PubMed ID: 19789838
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Independent Validation and Assay Standardization of Improved Metabolic Biomarker Signature to Differentiate Pancreatic Ductal Adenocarcinoma From Chronic Pancreatitis.
    Mahajan UM; Oehrle B; Sirtl S; Alnatsha A; Goni E; Regel I; Beyer G; Vornhülz M; Vielhauer J; Chromik A; Bahra M; Klein F; Uhl W; Fahlbusch T; Distler M; Weitz J; Grützmann R; Pilarsky C; Weiss FU; Adam MG; Neoptolemos JP; Kalthoff H; Rad R; Christiansen N; Bethan B; Kamlage B; Lerch MM; Mayerle J
    Gastroenterology; 2022 Nov; 163(5):1407-1422. PubMed ID: 35870514
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Inflammatory cytokines and combined biomarker panels in pancreatic ductal adenocarcinoma: Enhancing diagnostic accuracy.
    Kruger D; Yako YY; Devar J; Lahoud N; Smith M
    PLoS One; 2019; 14(8):e0221169. PubMed ID: 31415645
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.